肿瘤细胞治疗研究
英文原题：Building the future management of follicular lymphoma with T-cell-redirecting strategies.
滤泡性淋巴瘤（FL）通常需要多线治疗，而传统化学免疫治疗的疾病控制效果仍远不理想。
滤泡性淋巴瘤（FL）通常需要多线治疗，而传统化学免疫治疗的疾病控制仍远不充分。近期获批用于复发/难治性场景的若干T细胞重定向策略具有改善结局并改变FL治疗算法的潜力。本综述聚焦CAR-T细胞和双特异性抗体在FL中的作用，特别关注序贯治疗策略和未来方向。
Follicular lymphoma (FL) usually requires multiple lines of therapy, and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell-redirecting strategies recently approved in the relapsed/refractory setting have the potential to improve outcomes and change the treatment algorithm in FL. This review focuses on the role of chimeric antigen receptor T cells and bispecific antibodies in FL, paying special attention to sequencing approaches and future directions.
MEMBER ACCOUNT
登录成功会直接打开下一页。
